Diagnostic Performance of NLR, Type IV Collagen and Fibrosis Score in Chronic Hepatitis B
DOI:
https://doi.org/10.24293/ijcpml.v28i2.1826Keywords:
Type IV collagen, neutrophil lymphocyte ratio, APRI, FIB-4, liver fibrosis, chronic hepatitis BAbstract
Hepatitis B Virus (HBV) infection cause damage to the liver parenchym and continuous injury resulting in liver fibrosis. The neutrophil-lymphocyte ratio is a non-invasive marker of inflammation. Type IV collagen is a direct marker of hepatic fibrosis indicating transformation of the extracellular matrix of the liver, and its concentration is proportional to the degree of damaged liver cells and impaired liver function. APRI score and FIB-4 index are non-invasive methods for determining the degree of liver fibrosis. This study aimed to determine the performance of the neutrophil lymphocyte ratio, type IV collagen and fibrosis score on liver fibrosis in chronic hepatitis B. The study design was analytical observational with cross-sectional approach. The subjects included 42 chronic hepatitis B patients who admitted to Internal Medicine Department of Dr. Moewardi Hospital Surakarta from September to November 2020. The subject were grouped into fibrosis 21(50%) and non fibrosis groups 21(50%) based on transient elastography. Neutrophil lymphocyte ratio, type IV collagen and fibrosis score cut off point was determined with receiver operating curve (ROC) and diagnostic test was performed with 2x2 table. The cut-off point of 1.89 from the neutrophil lymphocyte ratio obtained sensitivity 61.9% and specificity of 38.1% with an AUC value of 0.524, while type IV collagen with a cut off point of 18.32 ng/mL obtained sensitivity 80.9% and specificity of 42.6% with an AUC of 0.642, a cut off 0.25 from the APRI score obtained a sensitivity of 81% and specificity of 61.9% with an AUC of 0.857, and cut-off FIB-4 of 0.68 obtained a sensitivity of 85.7% and specificity of 71.4 with AUC of 0.827. Neutrophil lymphocyte ratio with cutoff point of 1.89 has a weak diagnostic value on liver fibrosis in chronic hepatitis B. Further study by comparing or combining with other markers are needed. Type IV collagen with a cut off of 18.32 ng/mL, APRI score with a cut off of 0.25 and a FIB-4 index with a cut off of 0.68 can be used for screening liver fibrosis in chronic hepatitis B patients
Downloads
References
Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, et al. Hepatitis B Virus Infection: Overview. In: Tang H. Hepatitis B Virus Infection: Molecular Virology to Antiviral Drugs. Singapore: Springer Nature; 2020. p: 01-16.
Riset Kesehatan Dasar (Riskesdas). Laporan Nasional Riskesdas 2018. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Kementerian RI; 2019. p: 89-91.
European Association for the Study of the Liver. The summarized of EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. Turkish J. Gastroenterol. 2017; 28: 412-416. doi: 10.5152/tjg.2017.20817
Carmona I, Cordero P, Ampuero J, Rojas A, Romero-Gomez M. Role of assessing liver fibrosis in management of chronic hepatitis C virus infection. Clinical Microbiology and Infection. 2016; 22: 839-845.
Chin JL, Pavlides M, Moolla A, Ryan JD. Noninvasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy?. Front. Pharmacol. 2016; 7(159): 1-19.
Nallagangula KS, Nagaraj SK, Venkataswamy L, Chandrappa M. Liver fibrosis: A compilation on the biomarkers status and their significance during disease progression. Futur. Sci. OA. 2018; 4(1):FSO250. doi: 10.4155/fsoa-2017-0083
Shiha GES, Mousa N. Transient Elastography in Chronic Liver Diseases. In: Radu-Ionita F, Pyrsopoulus NT, Jinga M, Tintoiu IC, Sun Z, Bontas E. Liver Diseases: A Multidisciplinary Textbook. Switzerland: Springer Nature; 2020. p:545-552.
Kekilli M, Tanoglu A, Sakin YS, Kurt M, Ocal S, Bagci S. Is the neutrophil to lymphocyte ratio associated with liver fibrosis in patients with chronic hepatitis B ?. World J Gastroenterol. 2015; 21(18): 5575-5581. doi: 10.3748/wjg.v21.i18.5575
Peng Y, Li Y, He Y, Wei Q, Xie Q, Zhang L, et al. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis : a systematic review. Expert Rev. Gastroenterol. Hepatol. 2018; 12: 503–513. doi: 10.1080/17474124.2018.1463158
Sungkar T, Rozi MF, Dairi LB, Zain LH. Neutrophil-to-Lymphocyte Ratio (NLR) and its Correlation with Severity of Decompensated Liver Cirrhosis based on Child-Turcotte Pugh (CTP) Score. Journal of Clinical and Diagnostic Research. 2019; 13(2): 29-31. doi: 10.7860/JCDR/2019/39895.12618
Sand JMB, Genovese F, Gudmann MA, Karsdal MA. 2019. Type IV Collagen. In: Karsdal MA. 2nd ed. Biochemistry of Collagens, Laminins and Elastin: Structure, Function and Biomarkers. Elsevier; 2019. p: 31-41. doi: 10.1016/B978-0-12-817068-7.00004-5
Ghweil AA, Osman HA, Khodeary A. Diagnostic Efficacy of Serum Factor IV Collagen of Hepatic Fibrosis Regression in Chronic Hepatitis B Virus Infected Patients. Adv. Infect. Dis. 2018; 08: 241–254. doi: 10.4236/aid.2018.84020
Schiavon LDL, Narciso-Schiavon JL, De Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol. 2014; 20(11): 2854-2866.
Bakula A, Dadalski M. AST-to-Platelet Ratio Index (APRI) as Marker in Liver Disease. In: Preedy VR. Biomarkers in Liver Disease, Biomarkers in Disease: Methods, Discoveries and Applications. Dordrecht: Springer; 2015. p 1-16
Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, et al. Noninvasive Markers of Liver Fibrosis and Inflammation in Chronic Hepatitis B-Virus Related Liver Disease. Am J Gastroenterol. 2006; 101:2537-2545.
Demir NA, Kolgelier S, Ozcimen S, Gungor G, Sumer S, Demir LS, et al. Evaluation of the Relation Between Hepatic Fibrosis and Basic Laboratory Parameters in Patients With Chronic Hepatitis B Fibrosis and Basic Laboratory Parameters. Hepat Mon. 2014; 14(4):e16975
Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of Androgen Response Elements in the Enhancer I of Hepatitis B Virus: A Mechanism for Sex Disparity in Chronic Hepatitis B. Hepatology. 2009; 50(5):1392-1402.
Mobarak L. Effect of body mass index on Disease progression in Chronic Hepatitis B Patients. Curre Res Diabetes & Obes J. 2019; 9(3):1-4.
Lee IC, Huang YH, Chan CC, Huo TI, Chu CJ, Lai CR, et al. Impact of body mass index and viral load on liver histology in hepatitis B e antigen-negative chronic hepatitis B. Clinical Nutrition. 2011; 30:647-652.
Tapper EB, Afdhal NH. Noninvasive Assessment of Disease Progression. In: Sanyal AJ, Boyer TD, Lindor KD, Terrault NA. 7th ed. Zakim And Boyer's Hepatology: A Textbook Of Liver Disease. China: Elsevier; 2018. p:117-126e3.
Marks PW. Hematologic Manifestations of Liver Disease. Semin Hematol. 2013; 50:216-221.
Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. British Journal of Haematology. 2001; 113:10-595.
Yilmaz B, Aydin H, Can G, Senturk Z, Ustuner B, Yilmaz H, et al. The relationship between fibrosis level and blood neutrophil to lymphocyte ratio in inactive hepatitis B carriers. European Journal of Gastroenterology & Hepatology. 2014; 26:1325-1328.
He Q, He Q, Deng Y, He Y, Xie L, Li T, et al. The relationship between inflammatory marker levels and HBV-related cirrhosis severity. Int J Clin Exp Med. 2016; 9(11):22200-22205.
Liu K, Wang FS, Xu R. Neutrophils in liver diseases: pathogenesis and therapeutic targets. Cellular & Molecular Immunology. 2020; p: 1-7.
Yosry A, Fouad R, Alem SA, Elsharkawy A, El-Sayed M, Asem N, et al. FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol. 2016; p:1-6.
Teshale E, Lu M, Rupp LB, Holmberg SD, Moorman AC, Spralding P, et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). Journal of Viral Hepatitis. 2014; 21: 917-920.
Celikbilek M, Dogan S, Gursoy S, Zararsiz G, Yurci A, Ozbakir O, et al. Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol. 2013; 5(8):439-445.
Addissouky TA, El Agroudy AE, El-Torgoman AMAK, El Sayed IET, Ibrahim EM. Efficiency of alternative markers to assess liver fibrosis levels in viral hepatitis B patients. Biomedical Research. 2019; 30(2):1-6.
Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carilho FJ, et al. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Annals of Hepatology. 2020; p:1-6.
World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis b infection. World Health Organization; 2015. 134p.
Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT2 ULN. Medicine. 2017; 96:12(e6336).
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
